science wire

Novartis Global select country select business BOLERO-1 trial explored everolimus in women with HER2+ advanced breast cancer and did not meet criteria for statistical significance in first primary ob

Novartis Global select country select business Cosentyx showed superiority to Stelara ; meeting the primary endpoint of achieving PASI 90, which represents clear or almost clear skin at Week 16 and secondary endpoint of achieving PASI 75 at Week 4 for psoriasis patients CLEAR is the second head-to-head study for Cosentyx following the Phase III FIXTURE study that showed Cosentyx was superior to Enbrel (etanercept) CHMP recommended Cosentyx as fi

Fewer patients on Tasigna vs.

Data from ongoing trial reinforces the safety profile of Jakavi (ruxolitinib) as seen in previous Phase III studies Patients on Jakavi experienced a reduction in spleen size that was maintained over

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online as part of the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Holzkirchen, December 8, 2014 - Sandoz, a Novartis company, announced today Phase III data that demonstrat

Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions Additionally, sustained remissions were achieved up to one year or more with 6-month event-free survival of 70% and overall survival of 75%, in most cases without further therapy Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR'T cell therapies for the investi

Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia Studies targeting multiple cancer pathways in rare blood cancer m

PPMS is distinct from other types of MS, with no approved treatment that can change the course of this devastating disease Novartis remains strongly committed to identifying and developing treatment options for patients with chronic debilitating neurological conditions Basel, Dec 1, 2014 - Novartis announced today that the Phase III INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a combination of disability measures.

LCZ696 is the first investigational cardiovascular drug to be granted accelerated assessment, shortening the formal review clock by 60 days Approximately 15 million people in the EU live with heart f

Basel , November 25, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has extended their priority review period by up to three months for the new drug application (NDA)

Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the disease , , , Approval based on two large phase III trials sho

Cosentyx (secukinumab, formerly AIN457) is recommended as first-line systemic therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients in Europe In Phase III studies, 70% or

New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus enalapril Patients' and doctors' assessments of disease severity were also significantly better with LCZ696 than enalapril Effects on certain heart biomarkers indicate that compared to enalapril, LCZ696 reduced cardiac stress and damage Heart failure is hig

Secukinumab demonstrated significant and sustained efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA) in two pivotal studies - FUTURE 1 and FUTURE 2 are the first Phase III studies of a selective IL-17A inhibitor in PsA, a painful, debilitating condition causing inflammation of joints and skin , In FUTURE 1 more than 80% of secukinumab-treated patients experienced no progression of joint structural damage

More than 60% of secukinumab 150 mg patients achieved significant improvements in AS symptoms, seen as early as Week 1 and sustained through one year of treatment , Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies , Up to 40% of AS patients have inadequate or no response to standard of care anti-TNF (tumor-necrosis-factor) medicines

Power of One campaign, supported by exclusive treatment sponsor Novartis, raises funds for three million treatments for children with malaria Novartis associates rallied behind Power of One to fund c

Detailed results of four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 Secukinumab is the first selective interleukin-17A (IL-17A) inhibitor with Phase III data to demonstrate efficacy and improve symptoms in patients with PsA and AS Data will include study results from FUTURE 1 and FUTURE 2 in PsA and MEASURE 1 and MEASURE 2 in AS; data to be

Committee votes against recommending LBH589 plus bortezomib and dexamethasone for patients with previously treated multiple myeloma LBH589 has the potential to be an important treatment option for mu

Net sales up 4% (+5% cc) in Q3, with operating margin increase across Q3 and 9M Net sales of USD 14.7 billion grew 4% (+5% cc ) in Q3 Strong operating income growth in Q3 of 14% (+18% cc) Core

CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza seg

Roche presented development plans for its Basel site. Over the next 10 years, Roche will invest 3 billion Swiss francs in the development of its Basel site.

Secukinumab is the first selective IL-17A inhibitor to meet primary endpoint in two pivotal Phase III studies showing improvement in active ankylosing spondylitis (AS) patients' symptoms versus placebo AS is a painful, progressively debilitating condition associated with inflammation of the spine, causing irreversible consequences that significantly reduce patients' mobility and quality of life , Up to 40% of patients have an inadequate or no re

Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scientists from the Novartis Institutes for BioMedical Research (NIBR) show in a study that a promising therapeutic approach for metastatic breast cancer elicits deleterious effects after cessation of the treatment.

Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 FDA Advisory Committee recommendation based on efficacy and safety outcomes of 10 Phase II/III clinical studies of secukinumab in moderate-to-severe plaque psoriasis Affecting 7.5 million Americans, psoriasis may negatively impact daily life and is associated with increased r

Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL019 Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78% Novartis a

New analyses of Phase III data show consistent efficacy in clearing psoriasis skin with AIN457 (secukinumab) regardless of how bad patients' disease is at start of treatment Significant positive responses to secukinumab seen in patients with severe psoriasis at start of treatment Significant positive relationship between achieving clear to almost clear skin and psoriasis patients' health-related quality of life, as shown by additional secukinuma

Genentech, the US subsidiary of Roche, announced final survival results from the Phase III «Cleopatra» study, which showed that adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer by 15.7 months. According to Dr. Sandra Swain, an oncologist and professor at Georgetown University, this survival improvement is "unprecedented among studies of metastatic breast cancer”.

Most experts believe that combining immunotherapies with existing treatment options such as chemotherapies, radiation, targeted cancer therapies (and importantly also with cancer vaccines, many of wh

Johnson & Johnson announced a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion, all cash with no strings attached.

Phase I/II studies will evaluate Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational immunotherapy Opdivo Combination studies will evaluate compounds that have d

New data for the IL-17A inhibitor AIN457 (secukinumab) in psoriasis and Xolair in Chronic Spontaneous Urticaria (CSU) at EADV to highlight benefit to patients' quality of life Data continue to reinforce the landmark Phase III results of secukinumab in psoriasis and Xolair in CSU that showed consistent, fast efficacy and acceptable safety - Important head-to-head trial of secukinumab versus Stelara (CLEAR), powered to evaluate superiority in clea

Longest median progression-free survival (PFS) ever reported in this ALK+ non-small cell lung cancer patient population, most who received prior chemotherapy Zykadia (ceritinib) achieved overall resp

Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement Pancreatic NET (pNET) affects about 2&p

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels Signifor LAR (pasireotide) represents a potential new option for acromegaly

Roche launches Global Access Program for HIV viral load testing Program expands access to care supporting the Diagnostics Access Iniative Roche announced today the launch of a new Global Access Progr

Secukinumab met primary and key secondary endpoints in two pivotal Phase III studies showing superiority to placebo in patients with adult onset psoriatic arthritis (PsA) PsA is a debilitating, long-lasting condition that causes inflammation of joints and skin and affects up to 30% of people with psoriasis globally , Many people with PsA do not respond to current standard of care, with approximately 45% of people dissatisfied with current treatm

Results show statistically significant and clinically relevant increase in median progression-free survival with LBH589 plus bortezomib and dexamethasone LBH589, a first-in-class treatment for patients with relapsed/refractory multiple myeloma if approved, helps extend benefit of standard-of-care therapy First Phase III study to demonstrate superiority of a three-drug over two-drug combination in this patient population Multiple myeloma, the sec

Latest Zykadia data in patients with ALK+ non-small cell lung cancer, including updated brain metastases analysis from pivotal trial Final overall survival data from Phase III trial of Afinitor in ad

The University of Pennsylvania informed in a press release about an important milestone in its alliance with Novartis.

Retrospective analysis of US claims data suggests risk of endophthalmitis is 65% higher in patients treated with aflibercept than those treated with Lucentis Presentations discuss safety of Jetrea in

A key treatment goal for patients with MS is 'no evidence of disease activity' (NEDA), currently defined as no relapses, MRI lesions and disability progression Including MS-related brain shrinkage (brain volume loss) as a fourth key measure captures underlying damage that begins early in MS and is associated with loss of function The likelihood of achieving NEDA across four key measures was more than four-times greater in patients treated with G

Brain shrinkage is associated with a loss of physical and cognitive function and occurs at a faster rate in people with MS than those without the disease New data showed patients who had the highest rates of brain shrinkage (brain volume loss) at two years had a higher risk of disability progression at four years Separate analyses showed that patients continuously treated with Gilenya for six years had sustained low rates of brain shrinkage The

Once-daily Ultibro Breezhaler reduced exacerbations (flare ups) by 31% compared to twice-daily Seretide Accuhaler * in moderate-to-severe COPD patients LANTERN study further confirmed superiority of Ultibro Breezhaler in improving lung function compared to Seretide in moderate-to-severe COPD patients First presentation of LANTERN trial at European Respiratory Society International Congress involving over 700 COPD patients Basel, September 7, 201

'No evidence of disease activity' (NEDA), the ultimate treatment goal in MS, is currently assessed by measuring relapses, MRI lesions and disability progression New Gilenya data will highlight importance of brain shrinkage as NEDA fourth key measure, giving physicians more complete assessment of MS disease in patients Separate analyses will confirm the clinical relevance of brain shrinkage based on its association with future long-term MS disabi

First presentation of LANTERN study to confirm superior efficacy of once-daily Ultibro Breezhaler versus Seretide Accuhaler * in COPD patients QUANTIFY study to show superiority of Ultibro Breezhaler in lung function and shortness of breath versus tiotropium plus formoterol New data from GLISTEN study will provide important evidence for the benefits of once-daily Seebri Breezhaler as add on therapy to LABA/ICS** Basel, September 2, 2014 - Novart

Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen On all-cause mortality, LCZ696 doubled the effect that enalapril, an ACE-inhibitor, previously showed vs placebo when added to current best treatment for HF-REF , 26 million people across US and Europe live with heart failure , facing high risk of death and poor quality of life , Basel, August 30, 2014 - Tod

Global experts present potential solutions to support healthy aging from Novartis businesses and R&D organization The 11th annual event brings 60 top university students from 25 countries and ter

Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis Basel, August 20, 2014 - Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).